Description
INCB018424 is an inhibitor of JAK1/2 that is clinically used to treat rheumatoid arthritis and myelofibrosis. INCB018424 exhibits anticancer, anti-inflammatory, and antiviral activities. In myeloma cells, INCB018424 inhibits cell growth. INCB018424 also inhibits in vitro infection by HIV-1, HIV-2, and SHIV by preventing viral replication in lymphocytes. In animal models of CCL4-induced hepatic injury, INCB018424 prevents inflammation by decreasing neutrophil and macrophage infiltration, suppressing activation of NF-κB, and limiting release of TNF-α, IL-10, and IL-1β.
References
Springuel L, Hornakova T, Losdyck E, et al. Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. Blood. 2014 Dec 18;124(26):3924-31. PMID: 25352124.
Hazem SH, Shaker ME, Ashamallah SA, et al. The novel Janus kinase inhibitor ruxolitinib confers protection against carbon tetrachloride-induced hepatotoxicity via multiple mechanisms. Chem Biol Interact. 2014 Sep 5;220:116-27. PMID: 24973641.
Gavegnano C, Detorio M, Montero C, et al. Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrob Agents Chemother. 2014;58(4):1977-86. PMID: 24419350.
